+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Polymorphisms of the beta(2)-adrenergic receptor determine exercise capacity in patients with heart failure



Polymorphisms of the beta(2)-adrenergic receptor determine exercise capacity in patients with heart failure



Circulation Research 86(8): 834-840



The beta(2)-adrenergic receptor (beta(2)AR) exists in multiple polymorphic forms with different characteristics. Their relevance to heart failure (HF) physiology is unknown. Cardiopulmonary exercise testing was performed on 232 compensated HF patients with a defined beta(2)AR genotype. Patients with the uncommon Ile164 polymorphism had a lower peak VO(2) (15.0+/-0.9 mL. kg(-1). min(-1)) than did patients with Thr164 (17.9+/-0.9 mL. kg(-1). min(-1), P<0.0001). The percentage achieved of predicted peak VO(2) was also lower in patients with Ile164 (62. 3+/-4.5% versus 71.5+/-5.1%, P=0.045). The relative risk of a patient having a VO(2)

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 011166745

Download citation: RISBibTeXText

PMID: 10785504


Related references

Polymorphisms of the 2-Adrenergic Receptor Determine Exercise Capacity in Patients With Heart Failure. Circulation Research 86(8): 834-840, 2000

Polymorphisms of the beta-2 adrenergic receptor affect exercise capacity in patients with heart failure. Journal of Investigative Medicine 44(7): 394, 1996

Dissociation between exercise hemodynamics and exercise capacity in patients with chronic heart failure and marked increase in ejection fraction after treatment with beta-adrenergic receptor antagonists. American Journal of Cardiology 91(3): 356-360, 2003

Polymorphisms of the beta1-adrenergic receptor predict exercise capacity in heart failure. American Heart Journal 144(5): 840-846, 2002

Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenetics and Genomics 15(3): 137-142, 2005

Relationship between beta-1 adrenergic receptor polymorphisms and the response to beta-blockers in patients with heart failure. Circulation 104(17 Supplement): II 661-II 662, October 23, 2001

Beta2-adrenergic receptor polymorphisms influence the resting and exercise haemodynamics in the patients with chronic heart failure. European Heart Journal 24(Abstract Supplement): 247, August-September, 2003

Beta-2 adrenergic receptor gene polymorphisms Gln27Glu, Arg16Gly in patients with heart failure. Bmc Cardiovascular Disorders 9: 50, 2010

Effects of long-term beta-adrenergic blockade on exercise capacity in patients with chronic heart failure. Balady, G J, Pina, I L American Heart Association Monograph Series; Exercise and heart failure: 141-170, 1997

The Ile164 beta2-adrenergic receptor polymorphism is associated with decreased exercise capacity in patients with heart failure. Circulation 100(18 SUPPL ): I 247, Nov 2, 1999

Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure. Cardiovascular Drugs and Therapy 24(1): 49-60, 2010

Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients. British Journal of Clinical Pharmacology 71(4): 556-565, 2011

Association of beta-adrenergic receptor polymorphisms and progression to heart failure in patients with idiopathic dilated cardiomyopathy. American Journal of Medicine 117(7): 451-458, 2004

Exercise mediated changes in lymphocyte beta adrenergic receptor density in patients with heart failure. Circulation 76(4 PART 2): IV-308, 1987

Consideration of beta-1 adrenergic receptor polymorphisms along with traditional risk factors as predictors of prognosis in patients with heart failure. Clinical Pharmacology & Therapeutics 75(2): P55, 2004